Cargando…

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

BACKGROUND: A single-inhaler extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF) and glycopyrronium (G) has been developed for maintenance therapy of chronic obstructive pulmonary disease (COPD). This study evaluated the efficacy and safety of BDP/FF/G in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Jinping, Baldi, Simonetta, Zhao, Li, Li, Huiping, Lee, Kwan-Ho, Singh, Dave, Papi, Alberto, Grapin, Frédérique, Guasconi, Alessandro, Georges, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989027/ https://www.ncbi.nlm.nih.gov/pubmed/33757520 http://dx.doi.org/10.1186/s12931-021-01683-2

Ejemplares similares

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
por: Scichilone, Nicola, et al.
Publicado: (2014)

Extrafine inhaled corticosteroid therapy in the control of asthma
por: Ivancsó, István, et al.
Publicado: (2013)

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial
por: Beeh, Kai-Michael, et al.
Publicado: (2021)

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
por: Singh, Dave, et al.
Publicado: (2019)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
por: Singh, Dave, et al.
Publicado: (2020)

Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma
por: Gafar, Fajri, et al.
Publicado: (2018)

Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids
por: Postma, Dirkje S., et al.
Publicado: (2017)

The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN)
por: Skloot, Gwen S., et al.
Publicado: (2023)

Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
por: van der Molen, Thys, et al.
Publicado: (2016)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
por: Siddiqui, Salman H, et al.
Publicado: (2018)

Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study
por: Usmani, Omar S., et al.
Publicado: (2022)

How inhaled corticosteroids target inflammation in COPD
por: Lea, Simon, et al.
Publicado: (2023)

Erratum to: Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
por: van der Molen, Thys, et al.
Publicado: (2016)

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
por: Price, David B, et al.
Publicado: (2022)

Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany – The TriOptimize Study
por: Gessner, Christian, et al.
Publicado: (2022)

Asthma control in patients receiving inhaled corticosteroid and long-acting beta(2)-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation
por: Müller, Veronika, et al.
Publicado: (2011)

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations
por: Usmani, Omar S, et al.
Publicado: (2020)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

Inhaled corticosteroids in COPD: Personalising the therapeutic choice
por: Shaw, J A, et al.
Publicado: (2018)

Rational use of inhaled corticosteroids for the treatment of COPD
por: Quint, Jennifer K., et al.
Publicado: (2023)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β(2)-Agonist–Inhaled Corticosteroid Rescue
por: Lugogo, Njira, et al.
Publicado: (2023)

Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An In Silico Study
por: Usmani, Omar S., et al.
Publicado: (2021)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
por: Avdeev, Sergey, et al.
Publicado: (2019)

Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD
por: Lipworth, Brian, et al.
Publicado: (2021)

Extrafine HFA-beclomethasone-formoterol vs. nonextrafine combination of an inhaled corticosteroid and a long acting β2-agonist in patients with persistent asthma: A systematic review and meta-analysis
por: Liu, Ting, et al.
Publicado: (2021)

Inhaled Corticosteroids
por: Barnes, Peter J.
Publicado: (2010)

Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD
por: Cheng, Shih-Lung, et al.
Publicado: (2017)

Asthma progression and mortality: the role of inhaled corticosteroids
por: O'Byrne, Paul, et al.
Publicado: (2019)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

Inhaled corticosteroids can reduce osteoporosis in female patients with COPD
por: Liu, Shih-Feng, et al.
Publicado: (2016)

Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related
por: Koehorst-ter Huurne, Kirsten, et al.
Publicado: (2016)

Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal
por: Yawn, Barbara P, et al.
Publicado: (2016)

The dose of inhaled corticosteroids in patients with COPD: when less is better
por: Izquierdo, José Luis, et al.
Publicado: (2018)

COPD and Osteoporosis: Associated Factors in Patients Treated with Inhaled Corticosteroids
por: Ozcakir, Suheda, et al.
Publicado: (2020)

Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β(2)-agonist via dry-powder inhalers and pressurized metered-dose inhalers
por: Wittbrodt, Eric T, et al.
Publicado: (2018)

Patients with underuse or overuse of inhaled corticosteroids have different perceptions and beliefs regarding COPD and inhaled medication
por: Koehorst-ter Huurne, Kirsten, et al.
Publicado: (2018)

Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study
por: Martin, Richard J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5v5n7ev7opc8tpgdln4ohtm7cv